abbmira therapeutics AG
My visitor profile
abbmira therapeutics AG
Description of your activity
- Abbmira Therapeutics develops novel immune modulators for improved outcomes in cancer therapy. Abbmira has identified Compound42, an investigational small molecule designed to potentiate anticancer native immunity by reprogramming specific immune cells.
More information
- Abbmira has amassed significant pre-clinical data demonstrating that its experimental Compound42 enhances anticancer activity in relevant mouse models via macrophage activation. Compound42 binds to a defined intracellular target in tumor associated macrophages (TAMs), which activates these native immune cells to generate an anti-tumor microenvironment. Abbmira’s preclinical results validate the scientific rational of its therapeutic program and pave the way for biomarker-guided clinical development, either as monotherapy or in combination with standard-of-care anticancer therapies, in a clear drug-development path-to-market.
Emerging company
Marc CREUS
CEO, abbmira therapeutics
Date of your company creation:
- Less than 1 year
Main sector
- Biotechnology - Therapeutics and Diagnostics
Address
- Country : SWITZERLAND
- City : Basel
- Zip Code : 4057
Participation objectives
Partnering objectives
- Out-licensing / collaboration opportunities, Financing / investment opportunities, Network development
Description of my participation objective
- Abbmira Therapeutics AG offers an opportunity to invest towards a EUR 1.2M pre-seed round closing in 2025. These funds will be used for optimization & qualification of Compound42 into a lead-clinical candidate and for definition of clinical development path. We're also open to exploring collaborative opportunities with R&D labs and companies with relevant & complementary expertise in preclinical development.